Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Cai (Rotterdam, Netherlands), C. Van Der Ley (Groningen, Netherlands), M. Van Faassen (Groningen, Netherlands), I. Kema (Groningen, Netherlands), D. Duncker (Rotterdam, Netherlands), D. Merkus (Rotterdam, Netherlands). Activation of de novo NAD synthesis in the lung of pulmonary hypertension. 1419

Member's Comments

No comment yet.

Related content which might interest you: De novo interstitial fibrosis after pulmonary resection Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Effects of inhibitors of de novo pyrimidine synthesis on respiratory syncytial virus-induced inhibition of alveolar fluid clearance Source: Annual Congress 2004 - Cellular injury and repair in the lung Year: 2004 Polymorphisms in de novo glutathione biosynthesis genes affect lung function in heavy smokers Source: Eur Respir J 2007; 30: Suppl. 51, 448s Year: 2007 HFNT in acute de novo hypoxiemic patients Source: International Congress 2016 – Noninvasive ventilation versus high-flow nasal therapy for hypoxemic patients Year: 2016 De novo neoplasias and lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 725s Year: 2006 The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses Source: Eur Respir Rev 2009; 18: 260-271 Year: 2009 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Decreased glycolysis as metabolic footprint of endothelial cells in chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019 CONTRA and NO recommendation (excluding de novo respiratory failure) Source: ERS Course 2018 - Noninvasive ventilation: advanced Year: 2018 Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene Source: Eur Respir J 2004; 24: 30-39 Year: 2004 Functional upregulation of PRMT2 in chronic hypoxia-induced pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004 BMPR2 mutations and iron metabolism in pulmonary arterial hypertension patients Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Regulation disorders of pulmonary lipid metabolism in chronic obstructive pulmonary disease Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients Source: Eur Respir J 2010; 36: 682-683 Year: 2010 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002